GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Retained Earnings

Sinovac Biotech (Sinovac Biotech) Retained Earnings : $7,239.9 Mil (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sinovac Biotech's retained earnings for the quarter that ended in Jun. 2023 was $7,239.9 Mil.

Sinovac Biotech's quarterly retained earnings declined from Jun. 2022 ($7,623.4 Mil) to Dec. 2022 ($7,226.0 Mil) but then increased from Dec. 2022 ($7,226.0 Mil) to Jun. 2023 ($7,239.9 Mil).

Sinovac Biotech's annual retained earnings increased from Dec. 2020 ($144.2 Mil) to Dec. 2021 ($7,141.8 Mil) and increased from Dec. 2021 ($7,141.8 Mil) to Dec. 2022 ($7,226.0 Mil).


Sinovac Biotech Retained Earnings Historical Data

The historical data trend for Sinovac Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Retained Earnings Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.82 56.73 144.24 7,141.82 7,225.99

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,249.61 7,141.82 7,623.37 7,225.99 7,239.95

Sinovac Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Sinovac Biotech  (NAS:SVA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

Sinovac Amends Shareholder Rights Plan

By Business Wire Business Wire 02-22-2023

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022